The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Meta-analysis of cilta-cel in patients with R/R multiple myeloma
Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
